Nephrologie & therapeutique最新文献_第6页

Argumentaire justifiant la recherche des marqueurs virologiques essentiels pour la surveillance des patients hémodialysés chroniques 检测用于监测慢性血液透析患者的基本病毒标记物的理由

Nephrologie & therapeutique Pub Date : 2024-04-01 DOI: 10.1684/ndt.2024.73

Vincent Thibault

引用次数: 0

Argumentaire pour le suivi annuel des examens biologiques spécialisés réalisés en hémodialyse 血液透析专业生物检查年度监测指南

Nephrologie & therapeutique Pub Date : 2024-04-01 DOI: 10.1684/ndt.2024.75

Antoine Braconnier, Lucile Mercadal, Jean-Michel Poux

引用次数: 0

Pourquoi la littératie en santé est une composante essentielle de la santé des individus ayant une maladie rénale chronique 为什么健康知识是慢性肾病患者健康的重要组成部分？

Nephrologie & therapeutique Pub Date : 2024-04-01 DOI: 10.1684/ndt.2024.71

Lucile Paris, T. Lobbedez, Valérie Châtelet

引用次数: 0

Argumentaire justifiant le dosage des marqueurs biochimiques de routine en hémodialyse 血液透析中生化指标常规测量的依据

Nephrologie & therapeutique Pub Date : 2024-04-01 DOI: 10.1684/ndt.2024.74

C. Nodimar, P. Chauveau

引用次数: 0

Fibromuscular dysplasia of the renal arteries: what do we know in 2024? 肾动脉纤维肌性发育不良：2024 年我们知道些什么？

Nephrologie & therapeutique Pub Date : 2024-04-01 DOI: 10.1684/ndt.2024.70

Corentin Tournebize, Sandrine Lemoine, Caroline Pelletier

引用次数: 0

The highlights in nephrology in 2023 2023 年肾脏病学的亮点

Nephrologie & therapeutique Pub Date : 2024-03-01 Epub Date: 2024-02-12 DOI: 10.1684/ndt.2024.67

Mickaël Bobot, Sandrine Lemoine

引用次数: 0

The highlights of kidney transplantation in 2023 2023 年肾移植的亮点

Nephrologie & therapeutique Pub Date : 2024-03-01 Epub Date: 2024-01-31 DOI: 10.1684/ndt.2024.63

Sacha A De Serres, Lionel Couzi

{"title":"The highlights of kidney transplantation in 2023","authors":"Sacha A De Serres, Lionel Couzi","doi":"10.1684/ndt.2024.63","DOIUrl":"10.1684/ndt.2024.63","url":null,"abstract":"In 2023, significant advances were made in various areas of kidney transplantation. Firstly, the use of a balanced crystalloid solution in the recipient appears to prevent the delay in graft function, unlike hypothermia in the donor and normothermic pulsatile perfusion. Understanding the pathophysiology of humoral rejection has progressed, highlighting the major role of HLA class II molecules and innate immune cells (NK and monocytes expressing FCGR3A). An automatic Banff classification algorithm has been developed to better categorize biopsies in currently known diagnoses. CXCL10, combined with other variables, seems effective in ruling out rejection, but its role in routine care is yet to be defined. Regarding cytomegalovirus (CMV), letermovir has been proven effective in preventing CMV disease in D+R- patients, with fewer hematological side effects. For R+ patients, monitoring CMV-specific T-cell immunity is suggested to reduce the duration of antiviral prophylaxis. The only innovation in immunosuppression is imlifidase for highly sensitized patients, guided by French recommendations. A new equation for glomerular filtration rate measurement has been developed for kidney transplant recipients, performing well across various analyzed stratifications. Finally, xenotransplantation is making a comeback this year, generating hope. However, the description of early humoral rejections involving innate immune cells indicates that adjustments are still needed before considering its widespread deployment.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 S1","pages":"16-24"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients 血液透析患者慢性肾病相关瘙痒症的诊断和治疗

Nephrologie & therapeutique Pub Date : 2024-02-28 Epub Date: 2024-01-31 DOI: 10.1684/ndt.2024.60

Antoine Lanot, Laurent Misery, Guy Rostoker, Angelo Testa, Philippe Chauveau, Maxime Touzot, Nans Florens, Pierre Bataille

{"title":"Diagnosis and management of pruritus associated with chronic kidney disease in hemodialyzed patients","authors":"Antoine Lanot, Laurent Misery, Guy Rostoker, Angelo Testa, Philippe Chauveau, Maxime Touzot, Nans Florens, Pierre Bataille","doi":"10.1684/ndt.2024.60","DOIUrl":"10.1684/ndt.2024.60","url":null,"abstract":"Chronic kidney disease-associated pruritus (CKD-aP) is a disabling symptom which is frequent and often underestimated. Pa-MRC has a negative impact on quality of life, and is frequently accompanied by sleep disorders and depression. The approval of difelikefalin – a kappa opioid receptor agonist – in this indication requires updated recommendations. As a first step, secondary causes of pruritus without skin lesions must be ruled out, and general measures taken (emollients, psychological support, optimization of dialysis, normalization of serum calcium, phosphate and PTH in the range proposed by the KGIDO guidelines, treatment of iron deficiency). A therapeutic test with a non-sedating oral antihistamine may be proposed. If this test is negative, Pa-MRC must be strongly suspected, and its intensity (WI-NRS scale) and impact on quality of life assessed. In the case of mild Pa-MRC (WI-NRS ≤ 3), only general measures are implemented. If Pa-MRC is moderate to severe (WI-NRS ≥ 4), specific treatment with difelikefaline can be initiated for 6 months in addition to general measures. At 3 months, if the response is complete (WI-NRS score ≤ 1) or partial (decline ≥ 3 points), treatment is continued. At 6 months, if the response is complete, treatment may be discontinued with the patient’s agreement; treatment is maintained if the response is partial. At 3 or 6 months, if response is insufficient (decline < 3 points) and/or in the event of intolerance, treatment is discontinued and an alternative treatment (e.g., gabapentinoids, UVB) may be considered after dermatological consultation.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 1","pages":"50-60"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kidney biopsy for the diagnosis and treatment of kidney diseases. Recommendations from the French speaking Society of Nephrology (SFNDT) and French National Authority for Health (HAS) 2022 肾脏活检用于肾脏疾病的诊断和治疗。法国肾脏病学会（SFNDT）和法国国家卫生局（HAS）的建议 2022年

Nephrologie & therapeutique Pub Date : 2024-02-28 Epub Date: 2024-02-21 DOI: 10.1684/ndt.2024.68

Louis de Laforcade, Mickaël Bobot, Jean-Jacques Boffa, Christophe Bovy, Claire Cartery, Dominique Chauveau, Victor Gueutin, Corinne Isnard-Bagnis, Noémie Jourde Chiche, Alexandre Karras, Aimèle Meftah, Clotilde Müller, Pierre Sié, Thomas Stehlé, Laurence Vrigneaud, Vincent Vuiblet, Dominique Guerrot

引用次数: 0

Characteristics and prognosis of acute renal failure on dialysis in ANCA vasculitis ANCA 血管炎患者急性肾衰竭透析治疗的特点和预后

Nephrologie & therapeutique Pub Date : 2024-02-28 DOI: 10.1684/ndt.2024.58

Azria Siham, Fessi Hafedh, Boffa Jean-Jacques, Michel Pierre-Antoine

{"title":"Characteristics and prognosis of acute renal failure on dialysis in ANCA vasculitis","authors":"Azria Siham, Fessi Hafedh, Boffa Jean-Jacques, Michel Pierre-Antoine","doi":"10.1684/ndt.2024.58","DOIUrl":"10.1684/ndt.2024.58","url":null,"abstract":"Renal involvement in ANCA (Anti Neutrophil Cytoplasmic Antigen) vasculitis is common and is associated with increased mortality with a significant risk of progression to end-stage renal disease. The aim of this study is to investigate the epidemiological, clinicopathological, therapeutic and evolutionary characteristics of patients with ANCA vasculitis with acute renal injury, and to evaluate the impact of haemodialysis in the acute phase on mortality and renal recovery. Secondary objectives are to investigate other risk factors that impact on overall and renal survival. 31 patients were included ; the mean follow-up time was 30 months. The mean age was 68.52 years, and the sex ratio 0.72. All patients had acute renal failure, with histology revealing a mixed form in 45% of cases and a sclerotic form in 12.9% of cases. Pulmonary involvement was found in 58% of cases. 71% of patients had ANCA with anti-myeloperoxydase specificity, and 25.8% anti-proteinase 3 specificity. 32.2% of patients required haemodialysis, of which 60% were weaned. As initial treatment, 58.1% of patients received cyclophosphamide and 35.5% rituximab. The relapse rate was 6.5%. Infectious and cardiovascular complications affected more than half of the patients. The mortality rate was 19.35%. Comparing the two groups of patients dialysed in the acute phase and not dialysed, it appears that the overall and renal mortality was comparable. The progression to end-stage renal failure was higher in the dialysis patients. In a multivariate study, the presence of chronic kidney disease in the history and pulmonary involvement were associated with higher mortality.","PeriodicalId":94153,"journal":{"name":"Nephrologie & therapeutique","volume":"20 1","pages":"5-16"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139572473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0